SCHEMBL31396339

SCHEMBL31396339

CC(O)c1cc(C(=O)O)nc2c1CCCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.41
▸ POLB P06746 5/20 0.40
▸ L3MBTL1 Q9Y468 4/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ ALDH1A1 P00352 5/20 0.39
▸ TSHR P16473 3/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 3/20 0.39
▸ PRNP P04156 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ NCOA2 Q15596 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ NR2E3 Q9Y5X4 1/20 0.39
▸ NCOR2 Q9Y618 1/20 0.39
▸ CYP1A2 P05177 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31396136 0.85 ACHE (0.43) KDM4ENPSR1POLBMAPTALDH1A1
SCHEMBL18320638 0.76 POLB (0.43) KDM4ENPSR1POLBL3MBTL1TDP1
SCHEMBL16759802 0.75 TSHR (0.44) KDM4EPOLBL3MBTL1MAPTALDH1A1
SCHEMBL12072208 0.74 RXFP1 (0.48) KDM4ENPSR1POLBL3MBTL1TDP1
SCHEMBL20723122 0.73 KDM4E (0.45) KDM4ENPSR1POLBL3MBTL1TDP1
SCHEMBL18320768 0.69 KDM4E (0.40) KDM4ENPSR1POLBL3MBTL1TDP1
SCHEMBL18328058 0.67 KDM4E (0.39) KDM4ENPSR1POLBL3MBTL1TDP1
SCHEMBL31396038 0.67 ACHE (0.48) KDM4EPOLBMAPTALDH1A1GAA
SCHEMBL18320808 0.66 POLB (0.40) KDM4EPOLBL3MBTL1TDP1ALDH1A1
SCHEMBL28035983 0.66 ALOX15 (0.56) KDM4EALDH1A1TSHRPRNPRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739684-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
WO-2025008060-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
Send feedback